Firebrick announces USA Retail Launch Plan
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Firebrick Pharma Limited has announced its plan to enter the US retail pharmacy market for Nasodine products, following significant growth in online sales. The company has appointed Mr. Al Moghaddam as US Commercial Director to lead this initiative, with a phased approach to distribution through independent pharmacy groups and major retail chains. The announcement details a consulting agreement with Mr. Moghaddam, including a monthly fee and commission based on sales. Firebrick expects to benefit financially from the US operations through license fees and potential dividends, which could enhance profitability for the Australian entity.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Firebrick Pharma Limited on 6ix
Earlier from Firebrick Pharma
- Firebrick receives $293,000 R&D Tax Incentive
- Appendix 4E and Annual Report 30 June 2026
- Investor Update
- March 2026 Quarterly Activity Report & Appendix 4C
- Firebrick Secures $1.5 million via Placement
Later from Firebrick Pharma
- Firebrick Secures $732k in Strategic Investments
- Nasodine Nasal Spray Approved in the Philippines
- New Product - Nasodine Sinus Rinse
- September 2026 Quarterly Activity Report & Appendix 4C
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma